Longevity & Aging · Metabolic & Cardiometabolic
statin therapy increases type 2 diabetes risk to a degree greater than the small regulatory framing suggests
In plain terms: Do statins raise diabetes risk more than the small label suggests?
Partly supported and clinically important: statins clearly and reproducibly raise new-onset diabetes (about 9-12% relative, dose-dependent, higher in prediabetes), which is more than trivial for at-risk patients — but in most populations the CVD benefit still outweighs it.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (7)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Masson 2024 · Acta Diabetol | meta-analysis | mixed | moderate | Primary-prevention meta-analysis: diabetes risk concentrated in those with baseline diabetes risk factors (prediabetes/metabolic syndrome) — supports that magnitude is understated for at-risk subgroups while near-null for low-risk. |
| Thakker 2016 · Pharmacoepidemiol Drug Saf | meta-analysis | supports | moderate | Network meta-analysis of RCTs finds statins as a class raise new-onset diabetes risk, with heterogeneity by agent and dose. |
| Li 2025 · Cardiovasc Drugs Ther | meta-analysis | supports | moderate | Pooled analysis of statin adverse reactions across diseases quantifies elevated incidence of new-onset diabetes among statin users. |
| Preiss 2011 · JAMA | meta-analysis | supports | high | Intensive vs moderate statin dosing: additional 12% relative rise in new diabetes (OR 1.12), NNH about 498/year — establishes dose-dependence, strengthening more-than-a-footnote framing. |
| Singh 2024b venue: Expert Rev Clin Pharmacol · Expert Rev Clin Pharmacol | meta-analysis | mixed | moderate | Pitavastatin carries lower NODM risk than atorvastatin/rosuvastatin — shows risk is agent- and potency-dependent, not a uniform small class effect. |
| Seo 2022 · Cardiovasc Diabetol | observational | supports | high | Distributed-network analysis of 10 real-world databases confirms statins raise new-onset diabetes, with atorvastatin/rosuvastatin higher than pitavastatin. |
| Sattar 2010 · Lancet | meta-analysis | supports | high | 13 trials/91,140 patients: statins raised incident diabetes OR 1.09 (9% relative increase), about 1 extra case per 255 patient-years — real but modest; the foundational estimate. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.